LRRK2 and Parkinson disease: Similarly, trials like NCT04056689 and NCT04760769 are evaluating treatments such as DNL151, which targets the LRRK2 gene associated with PD, and Tavapadon, a dopamine agonist designed to modulate dopaminergic pathways in early PD.